Navigation Links
For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients
Date:4/2/2009

However, Most Surveyed MCOs Say They Will Not Provide Reimbursement for Xarelto if its Only Advantage in Stroke Prevention is Greater Convenience, According to a New Report from Decision Resources

WALTHAM, Mass., April 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for prevention of stroke, surveyed cardiologists estimate they will prescribe Bayer/Johnson & Johnson's Xarelto to 36 percent of newly-diagnosed atrial fibrillation patients, while primary care physicians (PCPs) estimate they will prescribe Xarelto to 29 percent of newly-diagnosed atrial fibrillation patients. Additionally, surveyed PCPs indicate they will prescribe Boehringer Ingelheim's Pradaxa to 28 percent of newly-diagnosed atrial fibrillation patients.

The new Physician & Payer Forum report entitled Novel Anticoagulants for Venous Thromboembolism and Stroke Prevention in Atrial Fibrillation: Will Prescribers' and Payers' Attitudes Promote or Prevent a Shift Away From Warfarin and Heparins? finds that Xarelto is the most popular emerging antithrombotic therapy among surveyed clinicians. Despite the proven effectiveness and widespread use of vitamin K antagonists such as warfarin (Bristol-Myers Squibb's Coumadin) for stroke prevention and heparins for venous thromboembolism prevention (VTE), both drug classes have drawbacks in safety and/or drug delivery that compromise optimal anticoagulation.

"A multitude of new anticoagulants currently in late-stage development are seeking to overcome these problems and developers of these agents could capitalize on the commercial potential offered by the large patient populations with atrial fibrillation or nonsurgical inpatients at risk of VTE," said Decision Resources Director Nikhil Mehta, M.Eng. "However, existing anticoagulants are well established, and older versions of these drugs are inexpensive--these factors beg the question as to whether or not prescribers and payers will support the uptake of new, more-expensive agents in this market."

The report finds that a third or fewer of surveyed managed care organizations' (MCO) pharmacy directors would place Xarelto, Pradaxa, or Bristol-Myers Squibb/Pfizer's apixaban on Tier 2 of their formularies if these agents are proven only to be equal to warfarin for both stroke prevention efficacy and bleeding. If the only clear advantage of these novel oral anticoagulants over warfarin in stroke prevention is greater convenience (e.g. no routine monitoring or dose adjustment), most surveyed pharmacy directors say they would be unwilling to pay for greater convenience alone.

Novel Anticoagulants for Venous Thromboembolism and Stroke Prevention in Atrial Fibrillation: Will Prescribers' and Payers' Attitudes Promote or Prevent a Shift Away From Warfarin and Heparins is based on a U.S. survey of 50 cardiologists, 31 hospital internists who sit on their hospital pharmacy and therapeutics committees, 72 primary care physicians and 20 managed care organization (MCO) pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                             Decision Resources, Inc.
    Christopher Comfort                            Elizabeth Marshall
    781-296-2597                                   781-296-2563
    ccomfort@dresources.com                        emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Trust for Americas Health Testifies before Congress on Building Prevention into Health Reform
2. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
3. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
4. Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009
5. Especially Among Children, Prevention is Key to Halting Obesity Epidemic, President of American Dietetic Association Tells Congressional Subcommittee
6. Recondo Technology Announces Authorization and Denial Prevention Software Service
7. Licorice compound offers new cancer prevention strategy
8. Poison Prevention Requires Diligence
9. Salt in Processed Foods Focus of the 7th National Forum on Heart Disease and Stroke Prevention
10. Preventium is where the prevention of breast and prostate cancer begins
11. NSC Hosts National Poison Prevention Week News Conference, Tuesday, March 17
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration ... to America. “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy ... country. , Nancy attributes her patriotic nature to her WWII veteran father. She ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ... cerebral cavernous angiomas, was awarded a grant from the Julian Grace Foundation to ... Mexico has more people with cavernous angioma than anywhere in the world. Most ...
(Date:12/7/2016)... ... , ... NuevaCare, a leading home care agency based in San Mateo but ... as part of its ambitious website relaunch. As Bay Area clients scramble to find ... serving their city. The new site has several key city-specific pages to address this ...
(Date:12/6/2016)... ... 06, 2016 , ... The International Vaccine Institute (IVI) and ... the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine ... deployment in the event of a future outbreak. , IVI and GeneOne held ...
(Date:12/6/2016)... ... December 06, 2016 , ... According to a November ... such as consuming too many mints or not drinking enough water, which can cause ... California Dental Care notes that good oral hygiene not only helps reduce the possibility ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... -- With opioids commonly used for pain management for workplace injuries, ... has led to nationwide fatalities. The synthetic opioid called ... heroin or morphine, resulting in likelihood of addiction, abuse or death. ... , , ... Behavioral Health for HMC HealthWorks, explained the opioid drug is less ...
(Date:12/6/2016)... new study released today by the Alliance for ... Drug Pricing Program will continue to expand at an unprecedented ... exceed $23 billion in total purchases at the 340B price. ... Part B drug reimbursement purchases over the next five years. ... of data on total drug purchases through 340B from 2005 ...
Breaking Medicine Technology: